Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 811 to 820 of 2588 total matches.
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
-aooe (Aimovig), which targets the CGRP
receptor, was the first.1
Fremanezumab (Ajovy ...
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and galcanezumab
are the second and third subcutaneously
injected monoclonal antibodies that target the CGRP
pathway to be approved by the FDA for this indication;
erenumab-aooe (Aimovig), which targets the CGRP
receptor, was the first.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
persons in the US had hepatitis C
between 2017 and 2020.1 Guidelines from the American
Association ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Drugs for Breast Cancer
Treatment Guidelines from The Medical Letter • Jan 01, 2005 (Issue 29)
from The Medical Letter
®
1
Drugs for Breast Cancer
In addition to surgery and radiation therapy, a variety ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Drugs for Bipolar Disorder
Volume 66 (Issue 1699) April 1, 2024
Bipolar disorder is characterized ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
. Guidelines for treatment of UC and CD
have been updated in recent years.1,2
AMINOSALICYLATES ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Interferon Beta-1b for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993 (Issue 900)
relapsing-remitting MS compared placebo, 1.6 million international units (IU) of
interferon beta-1b, and 8 ...
Interferon β-1b (Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).
Cephalosporins for Patients with Penicillin Allergy
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012 (Issue 1406)
a
penicillin.1
HISTORY OF ALLERGY — Patients with a history of an
IgE-mediated reaction to a penicillin ...
Only a small minority of patients who say they are
allergic to penicillin will have a reaction if they take a
penicillin.
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013 (Issue 1415)
(GIST).
Grade 3 or higher adverse effects occur in about 50%
of patients. o
1. A Grothey et al ...
Regorafenib (Stivarga – Bayer), a multikinase inhibitor,
has been approved by the FDA for treatment of
patients with metastatic colorectal cancer previously
treated with multiple other regimens specified in the
labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or
metastatic gastrointestinal stromal tumor (GIST).
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
more than in any previous year.1 Several guidelines on
the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction